Overview

An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer

Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
This observational study evaluates the efficacy and safety of capecitabine in combination with oxaliplatin in the adjuvant setting in participants with Stage III colon cancer. Data were collected from each participant for up to 36 months or until disease recurrence.
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Capecitabine
Oxaliplatin